Evidence map›Paper›PMID 35373192›Full record

ArticleJournal of cellular immunology2022

Glucose Metabolism is a Better Marker for Predicting Clinical Alzheimer's Disease than Amyloid or Tau.

Tyler C Hammond, Ai-Ling Lin

Abstract readComment
In one paragraph

Article in Journal of cellular immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: A pilot single-arm trial.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer's disease in an APOE genotype-dependent manner.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. The Key Role of Mitochondrial Function in Health and Disease.Antioxidants (Basel, Switzerland) · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Tyler C HammondSanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.
Ai-Ling LinSanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA.

Funding

University of Kentucky Alzheimer's Disease Research CenterP30AG072946 · NIA · UNIVERSITY OF KENTUCKY · PI LINDA J VAN ELDIK · 2021 to 2026
$23.5M
Supplement to Prebiotics Intervention to Reduce Alzheimer's Disease Risk via Brain-Gut Axis in an APOE4 Mouse ModelRF1AG062480 · NIA · UNIVERSITY OF MISSOURI-COLUMBIA · PI LIN, AI-LING · 2019 to 2020
$3.6M
Multi-Modal MRI to Assess Alzheimer's Disease Prevention in an APOE4 MouseModelR01AG054459 · NIA · UNIVERSITY OF MISSOURI-COLUMBIA · PI LIN, AI-LING · 2017 to 2021
$3.0M
Training in Translational Research in Alzheimer's and Related Dementias (TRIAD)T32AG057461 · NIA · UNIVERSITY OF KENTUCKY · PI MURPHY, MICHAEL PAUL, VAN ELDIK, LINDA J · 2017 to 2021
$2.1M
NIA NIH HHS P30 AG072946NIA NIH HHS R01 AG054459NIA NIH HHS RF1 AG062480NIA NIH HHS T32 AG057461
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID35373192
PMCPMC8975178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.